MARKET

ISEE

ISEE

Iveric Bio Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

9.40
-0.22
-2.29%
After Hours: 9.80 +0.4 +4.26% 16:49 07/01 EDT
OPEN
9.64
PREV CLOSE
9.62
HIGH
9.84
LOW
9.15
VOLUME
1.55M
TURNOVER
0
52 WEEK HIGH
19.35
52 WEEK LOW
6.30
MARKET CAP
1.09B
P/E (TTM)
-8.2951
1D
5D
1M
3M
1Y
5Y
Insider Buy: Iveric Bio
MT Newswires · 06/14 17:16
Iveric Bio Announces Presentation of Post-Hoc Analysis at Macula Society from GATHER1 Clinical Trial of Zimura® in Patients with Geographic Atrophy
PARSIPPANY, N.J., June 10, 2022--Iveric Bio announced its presentation of a post-hoc analysis from the Zimura GATHER1 clinical trial at the Macula Society Meeting in Berlin, Germany.
Business Wire · 06/10 11:00
IVERIC Bio stock rises after BofA, Guggenheim initiate with buy ratings
Shares of IVERIC Bio (NASDAQ:ISEE) have added 4.4% to $11.46 in Wednesday morning trading, after both Bank of America and Guggenheim initiated the stock with buy ratings. BofA's price target for ISEE
Seekingalpha · 06/08 15:46
IVERIC Bio Shares Rise After BofA Securities, Guggenheim Start Coverage at Buy
MT Newswires · 06/08 13:15
IVERIC bio, Inc. (NASDAQ:ISEE) insiders are still down US$16k after purchasing last year, recent gain helped regain some losses
Insiders who bought US$50k worth of IVERIC bio, Inc. ( NASDAQ:ISEE ) stock in the last year recovered part of their...
Simply Wall St. · 06/08 11:08
BofA Securities Starts IVERIC bio at Buy With $18 Price Target
MT Newswires · 06/08 06:46
Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PARSIPPANY, N.J., June 02, 2022--Iveric Bio granted equity-based awards pursuant to the Company’s 2019 Inducement Stock Incentive Plan to eight newly-hired, non-executive employees.
Business Wire · 06/02 12:00
Credit Suisse Lifts IVERIC bio's Price Target to $24 from $22, Maintains Outperform Rating
MT Newswires · 05/20 11:35
More
No Data
Learn about the latest financial forecast of ISEE. Analyze the recent business situations of Iveric Bio Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 11 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

54.55%Strong Buy
36.36%Buy
9.09%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average ISEE stock price target is 24.00 with a high estimate of 30.00 and a low estimate of 12.00.
High30.00
Average24.00
Low12.00
Current 9.40
EPS
Actual
Estimate
-0.26-0.19-0.13-0.06
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 212
Institutional Holdings: 126.60M
% Owned: 108.74%
Shares Outstanding: 116.42M
TypeInstitutionsShares
Increased
62
10.72M
New
20
5.72M
Decreased
56
5.69M
Sold Out
30
10.54M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+2.10%
Pharmaceuticals & Medical Research
+0.97%
Key Executives
Non-Executive Chairman/Independent Director
Adrienne Graves
President
Pravin Dugel
Chief Executive Officer/Director
Glenn Sblendorio
Chief Financial Officer/Senior Vice President/Treasurer
David Carroll
Chief Operating Officer/Senior Vice President
Keith Westby
Executive Vice President
Anthony Gibney
Senior Vice President
Christopher Simms
Independent Director
Mark Blumenkranz
Independent Director
Axel Bolte
Independent Director
Jane Henderson
Independent Director
Christine Miller
Independent Director
Calvin Roberts
No Data
No Data
About ISEE
IVERIC bio, Inc. is a biopharmaceutical company. The Company is engaged in the discovery and development of treatment options for retinal diseases. The Company is developing both therapeutic product candidates for age-related retinal diseases and gene therapy product candidates for orphan inherited retinal diseases (IRDs). The Company's therapeutics portfolio consists of Zimura (avacincaptad pegol), a complement C5 inhibitor, and IC-500, a high-temperature requirement A serine peptidase 1 protein (HtrA1) inhibitor. The Company's gene therapy portfolio consists of two product candidates in pre-clinical development, IC-100 and IC-200. The Company is developing IC-100 for rhodopsin-mediated autosomal dominant retinitis pigmentosa (RHO-adRP) and IC-200 for bestrophin-1 (BEST1) related IRDs.

Webull offers kinds of IVERIC bio Inc stock information, including NASDAQ:ISEE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ISEE stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ISEE stock methods without spending real money on the virtual paper trading platform.